|
[1]
|
Weiner RE, Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases[J]. Apple Radiat Isot, 2002, 57(5):749-763. |
|
[2]
|
Anthony LB, Woltering EA, Espenan GD, et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies[J]. Semin Nucl Med, 2002, 32(2):123-132. |
|
[3]
|
Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with[In-DTPA] octreotide:the Rotterdam experience[J]. Semin Nucl Med, 2002, 32(2):110-122. |
|
[4]
|
Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular for in vivo multireceptor tomour targeting[J]. Eur J Ncul Med Mol Imaging, 2002, 29(7):855-862. |
|
[5]
|
Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of the somatostatin receptor subtypes2,3 and 5 forLabelling with various radiometals[J]. Eur J Nucl Med Mol Imaging, 2003, 30(10):1338-1347. |
|
[6]
|
Kwekkeboom DJ, Kooij PP, Bakker WH, et al. Comparison of 111InDOTA-Thy3-octreotide and 111In-DTPA-octreotide in the same patients:biodistribution, kinetics organ and tumor uptak[J]. J Nucl Med, 1999, 40(5):762-767. |
|
[7]
|
Chinol M, Bodei L, Cremonesi M, et al. Receptor-mediated radiotherapy with 90Y-DOTA-dphe-Thy-octreotide:the experience of the European Institute of Oncology Group[J]. Semin Nucl Med, 2002, 32(2):141-147. |
|
[8]
|
Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4GBq 90Y-DOTATOC[J]. J Nucl Med, 2002, 43(5):610-616. |
|
[9]
|
Waldherr C, Schumacher T, Maecke HR, et al. Does tumor response depend on the number of treatment sessions at constant injected dose using 90-yttrium-DOTATOC in neuroendocrine tumors?[J].Eur J Nucl Med, 2002, 29(Suppl):S100. |
|
[10]
|
De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors:preclinical and clinical findings[J].Semin Nucl Med, 2002, 32(2):133-140. |
|
[11]
|
Jonard P, Jamar F, Walrand S, et al. Tumor dosimetry based on PET86Y-DOTA-Tyr3-octreotide(SMT487)and CT-scan predicts tumor response to 90Y-SMT487(OctreoTher)[J]. J Nucl Med, 2000, 41(Suppl):111P. |
|
[12]
|
Schumacher T, Hofer S, Eichhorn k, et al. Local injection of the 90Ylabelled peptidc vector DOTATOC to control gliomas of WHO grades Ⅱ and Ⅲ:an extended pilot study[J]. Eur J Nucl Med Mol Imaging,2002, 29(4):486-493. |
|
[13]
|
Virgolini I, Britton K, Buscombe J, et al. In-and Y-DOTA-lanreotide:results and implications of the MAURITIUS trial[J]. Semin Nucl Med,2002, 32(2):148-155. |
|
[14]
|
Kwekkeboom DJ, Bakker WH, Kooij PPM, et al.[177Lu-DOTAO,Thy3] octreotate:comparison with[111In-DOTA0] octreotide in patiens[J]. EurJ Nucl Med, 2001, 28(9):1319-1325. |
|
[15]
|
Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patient with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue[177Lu-DOTA (0), Thy3] octreotate[J].EurJ Nucl Med Mol Imaging, 2003, 30(3):417-422. |
|
[16]
|
Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate:relation to neoplastic transformation[J]. Cancer Res,1999, 59(5):1152-1159. |
|
[17]
|
Gugger M, Reubi JC. Gastrin-releasing peptide receptors in nonneoplastic and neoplastic human breast[J]. Am J Pathol, 1999, 155(6):2067-2076. |
|
[18]
|
De Jong M, Breeman WA, Bernard BF, et al. Tumor Response After[(90)Y-DOTA(0), Thy(3)] octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size[J]. Eur J Nucl Med, 2001,42(12):1841-1846. |
|
[19]
|
De Jong M, Beraard BF, Breeman WAP, et al. Combination of 90Yand 177Lu-labelled somatostatin analogs is superior for radionuclide therapy compared to 90Y-or 177Lu-labelled analogs only[J]. J Nucl Med,2002, 43(Suppl):123P-124P. |
点击查看大图
下载: